All In Biotech

Drug Trial Radar · NCT05273827

Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium

Clinical Observation of the Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium in Patients With Non-small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Jan 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

81

Actual

Start

Mar 22, 2022

Primary completion

Dec 20, 2023

Study completion Jan 2, 2024

Sponsor

Lead sponsor
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Tianjin Medical University General Hospital; Tianjin Chest Hospital
First posted
Mar 10, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To observe the effect of preoperative anti-PD-1 monotherapy combined with chemotherapy on patients' perioperative pain and opioid analgesia, and evaluate its effect on the incidence and severity of patients' postoperative delirium.

Conditions

  • Immunotherapy
  • Analgesia
  • NSCLC
  • Delirium

Interventions

  • neoadjuvant immunotherapyDrug

    Anti-PD-1 antibody was added to the conventional neoadjuvant chemotherapy.

  • Neoadjuvant chemotherapyDrug

    Cis-platinum combined with paclitaxel or pemetrexed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. perioperative opioids consumptionTime frame: from beginning of surgery to day 3 after surgery

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Tianjin Chest Hospital

    Tianjin, China

  • Tianjin Medical University General Hospital

    Tianjin, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.